Q301--Cytopathology and Thyrosequence Testing Service | SAM.gov Opportunity | G2X

Q301--Cytopathology and Thyrosequence Testing Service

Solicitation36C24221Q1521Notice typeSpecial Notice

Attachments

1 file

Name	Type	Posted	Actions
36C24221Q1521.docx	DOCX	Sep 23, 2021	Download

Version History

Q301--Cytopathology and Thyrosequence Testing Service

Special Notice36C24221Q1521Sep 23, 2021 · v3

LatestViewing

Opportunity Summary

The Department of Veterans Affairs, Network Contracting Office 2, intends to award a sole-source, firm-fixed-price, indefinite delivery contract to Cytopath Biopsy Lab, Inc. for cytopathology and Thyrosequence testing services. This requirement, identified under solicitation number 36C24221Q1521, supports the Northport VA Medical Center in Northport, New York, with an anticipated effective date of October 1, 2021. The proposed contract structure includes a one-year base period with four one-year options to provide approximately 96 tests annually.

The scope of work involves the analysis of patient samples obtained through fine needle aspirate biopsies. Initially, samples undergo a cytopathology assessment; if the results are indeterminate for specific thyroid nodules in patients 21 or older, the contractor performs ThyroSeq Genomic Classifier next-generation gene sequencing. This process analyzes DNA and RNA across 112 thyroid-related genes to identify molecular alterations, providing a genomic classifier report to aid in diagnosis.

This procurement is classified under NAICS 621511 Medical Laboratories and PSC Q301 MEDICAL- LABORATORY TESTING. The Veterans Affairs contracting office has cited 41 U.S.C. 1901 as the authority for the sole-source award, based on the determination that only one responsible source can satisfy the agency’s requirements. Brad Mills is the designated contracting officer for this notice, which includes one attached document, 36C24221Q1521.docx, published on September 23, 2021.

Generated by Lumen AI

Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.

Opportunity Summary

Opportunity Details

Response deadline: —No deadline provided
NAICS: 621511 (opens in new tab)
PSC: Q301 (opens in new tab)
Set aside: —
Published: Sep 23, 2021
Updated: Sep 23, 2021
Agency: VETERANS AFFAIRS, DEPARTMENT OF
Office: VETERANS AFFAIRS, DEPARTMENT OF
Department: —
Source: View on SAM.gov (opens in new tab)

Contact and place of performance

Point of contact: Brad Mills

Place of performance: Not specified

Original Description

NOTICE OF INTENT. The Department of Veterans Affairs, Network Contracting Office 2 intends to solicit and award a sole-source, firm-fixed-price, Indefinite Delivery Contract (with individual task orders issued for the annual ordering periods) with Cytopath Biopsy Lab, Inc. (760 Westchester Ave., Rye Brook, NY 10573-1341) in accordance with 41 U.S.C. 1901, as implemented by FAR 13.106(b)(2)(i): Only one responsible source and no other supplies or services will satisfy agency requirements. The contract anticipated effective date is October 1, 2021 for one year with four option years. This contract is for Cytopathology & Thyrosequence Testing Service. Contractor shall provide for the Northport VA Medical Center (79 Middleville Rd., Northport, NY 11768) approximately 96 tests per year. Patient samples obtained through fine needle aspirate (FNA) biopsies are collected for both cytopathology assessment and ThyroSeq GC. Initially cytopathology assessment is conducted. If the cytopathology diagnosis is benign, suspicious for malignancy, malignant or non-diagnostic, the Cytopathology FNA Analysis is complete. If the cytopathology diagnosis is indeterminate [includes Follicular lesion of Undetermined Significance (FLUS)/Atypia of Undetermined significance (AUS) and (suspicious for) Hurthle/Follicular Neoplasm], the thyroid nodule is greater than or equal to 1 cm and the patient is 21 or older, The ThyroSeq GC Next Generation gene sequencing is performed. ThyroSeq Genomic Classifier (GC) test utilizes next-generation sequencing to analyze DNA and RNA of 112 thyroid-related genes for four main classes of molecular alterations, including mutations, gene fusions, copy number alterations, and gene expression alterations. The results are processed by a unique Genomic Classifier (GC) and reported as Positive or Negative. The NAICS code is 621511 (Medical Laboratories) with a small business size standard of $35 Million. This is for informational purposes only and is not be construed as a commitment by the Government. This is not a request for offers. A determination by the Government not to compete this procurement based upon responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct future competitive procurements for this item. Point of Contact is Brad Mills, Contracting Officer, at email [email protected], phone 914.737.4400 x202074.